Zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+(CLDN18.2+) / HER22 locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study-MedSci.cn

Zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+(CLDN18.2+) / HER22 locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study

Shitara, K; Lordick, F; Bang, YJ; Enzinger, PC; Ilson, DH; Shah, MA; Van Cutsem, E; Xu, RH; Aprile, G; Xu, JM; Chao, J; Pazo-Cid, R; Kang, YK; Yang, JN; Moran, DM; Bhattacharya, PP; Arozullah, A; Park, JW; Ajani, JA

JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (): LBA292

科室
- - 订阅+
  - 更多科室
工具
服务